David B. Weiner, Ph.D.

David B. Weiner, Ph.D.

  • Executive Vice President
  • Director, Vaccine & Immunotherapy Center
  • W.W. Smith Charitable Trust Professor in Cancer Research
  • dweiner@wistar.org
Summary

Dr. Weiner directs a translational research laboratory in the area of Molecular Immunology.  His group is one of the pioneering research teams in establishing the field of DNA vaccines and immune therapies.  Important reports from his lab include the first DNA vaccine studied for HIV as well as for cancer immune therapy, the early development of DNA encoded genetic adjuvants including the particularly relevant IL-12, advances in gene optimization, and advances in electroporation technologies resulting in improved gene delivery among others. His group worked with collaborators to become the first to move DNA technology into human study.  His laboratory's work helped revitalize the field through advancement of new synthetic DNA design and modification of EP delivery approaches resulting in potent immune induction as well as the first successful Phase IIb DNA efficacy study (for HPV immune therapy) in humans.

Weiner is the recipient of numerous honors including election as a fellow to both the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He is the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy.

Weiner returns to Wistar from his position at The University of Pennsylvania School of Medicine as professor of Pathology and Laboratory Medicine. From 1990 to 1993, Weiner held a joint position as assistant professor of Pathology and Laboratory Medicine at The Wistar Institute and the University of Pennsylvania School of Medicine.

Weiner graduated with a B.S. in biology from SUNY at Stony Brook, in Stony Brook, N.Y., a M.S. in biology from the University of Cincinnati and a Ph.D. in developmental biology from the University of Cincinnati College of Medicine.

Selected Publications

1. Muthumani K, Block P, Flingai S, Muruganantham N, Chaaithanya IK, Tingey C, Wise M, Reuschel EL, Chung C, Muthumani A, Sarangan G, Srikanth P, Khan AS, Vijayachari P, Sardesai NY, Kim JJ, Ugen KE, Weiner DBRapid and long-term immunity elicited by DNA encoded antibody prophylaxis and DNA vaccination against Chikungunya virus. J Infect Dis. 2016 Mar 21. pii: jiw111. [Epub ahead of print] PMID:27001960

2. Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.  Lancet. 2015 Nov 21;386(10008):2078-88. doi: 10.1016/S0140-6736(15)00239-1. Epub 2015 Sep 17.  PMID: 26386540

3. Muthumani K, Falzarano D, Reuschel EL, Tingey C, Flingai S, Villarreal DO, Wise M, Patel A, Izmirly A, Aljuaid A, Seliga AM, Soule G, Morrow M, Kraynyak KA, Khan AS, Scott DP, Feldmann F, LaCasse R, Meade-White K, Okumura A, Ugen KE, Sardesai NY, Kim JJ, Kobinger G, Feldmann H, Weiner DBA synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.  Sci Transl Med. 2015 Aug 19;7(301):301ra132. doi: 10.1126/scitranslmed.aac7462.  PMID:26290414

4. Flingai S, Plummer EM, Patel A, Shresta S, Mendoza JM, Broderick KE, Sardesai NY, Muthumani K, Weiner DBProtection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy.  Nature Sci Rep. 2015 Jul 29;5:12616. doi: 10.1038/srep12616.  PMID:26220099

5. Kutzler MA, Wise MC, Hutnick NA, Moldoveanu Z, Hunter M, Reuter MA, Yuan S, Yan J, Ginsberg AA, Sylvester A, Pahar B, Carnathan DG, Kathuria N, Khan AS, Montefiori D, Sardesai NY, Betts MR, Mestecky J, Marx PA, Weiner DBChemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge. Nature Mucosal Immunol. 2016 Jan;9(1):13-23. doi: 10.1038/mi.2015.31. Epub 2015 May 6.  PMID: 25943275

6. Yan J, Pankhong P, Shin TH, Obeng-Adjei N, Morrow MP, Walters JN, Khan AS, Sardesai NY, Weiner DBHighly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity.  Cancer Immunol Res. 2013 Sep;1(3):179-89. doi: 10.1158/2326-6066.CIR-13-0001. Epub 2013 Jul 17.  PMID: 24777680

7. Kalams SA, Parker SD, Elizaga M, Metch B, Edupuganti S, Hural J, De Rosa S, Carter DK, Rybczyk K, Frank I, Fuchs J, Koblin B, Kim DH, Joseph P, Keefer MC, Baden LR, Eldridge J, Boyer J, Sherwat A, Cardinali M, Allen M, Pensiero M, Butler C, Khan AS, Yan J, Sardesai NY, Kublin JG, Weiner DB; NIAID HIV Vaccine Trials Network.  Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.  J Infect Dis. 2013 Sep 1;208(5):818-29. doi: 10.1093/infdis/jit236. Epub 2013 Jul 8.  PMID: 23840043

8. Shedlock DJ, Aviles J, Talbott KT, Wong G, Wu SJ, Villarreal DO, Myles DJ, Croyle MA, Yan J, Kobinger GP, Weiner DB. Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.  Mol Ther. 2013 Jul;21(7):1432-44. doi: 10.1038/mt.2013.61. Epub 2013 May 14.  PMID: 23670573

9. Bagarazzi ML, Yan J, Morrow MP, Shen X, Parker RL, Lee JC, Giffear M, Pankhong P, Khan AS, Broderick KE, Knott C, Lin F, Boyer JD, Draghia-Akli R, White CJ, Kim JJ, Weiner DB, Sardesai NY.  Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses.  Sci Transl Med. 2012 Oct 10;4(155):155ra138. doi: 10.1126/scitranslmed.3004414. PMID:23052295

10. Morrow MP, Pankhong P, Weiner DBDesign and characterization of a plasmid vector system capable of rapid generation of antibodies of multiple isotypes and specificities.  Biotechnol Lett. 2009 Jan;31(1):13-22. doi: 10.1007/s10529-008-9826-y. Epub 2008 Sep 6.  PMID:18777012